Form 4: Interpace Biosciences CFO Christopher McCarthy Reports Stock Transactions

Christopher McCarthy, CFO of Interpace Biosciences, reports the vesting of restricted stock units and subsequent withholding of shares to cover tax obligations.

Summary

• Christopher McCarthy, the Chief Financial Officer of Interpace Biosciences, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• The report covers transactions from July 31, 2023, to December 1, 2024, primarily involving the vesting of restricted stock units (RSUs).
• Upon vesting of the RSUs, a portion of the shares were withheld by the issuer to satisfy federal and state tax obligations.
• McCarthy relinquished these withheld shares, which the issuer then cancelled and returned to treasury.
• These transactions did not involve any sales of shares by McCarthy.
• As a result of these transactions, McCarthy's direct ownership of Interpace Biosciences common stock increased from 15,872 to 46,791 shares.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment. It simply reports transactions related to executive compensation. There are no explicit positive or negative implications for the company's performance or outlook.

Positives

• The vesting of restricted stock units suggests that McCarthy is meeting performance milestones or time-based vesting requirements.
• The transactions are compliant with Section 16b-3(e) of securities regulations, indicating proper handling of tax obligations related to equity compensation.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into the stock ownership of company insiders. The vesting of RSUs is a common practice in the biotechnology industry to incentivize and retain key personnel.

Comparison to Industry Standards

• Equity compensation practices, including the use of restricted stock units, are common among publicly traded biotechnology companies.
• Companies like Exact Sciences (EXAS) and Guardant Health (GH) also utilize RSUs as part of their executive compensation packages.
• The specific number of RSUs granted and the vesting schedules vary depending on the company's size, performance, and compensation philosophy.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• Shareholders may view the vesting of RSUs as a sign that the executive is meeting performance goals.
• The withholding of shares for tax obligations is a standard practice and does not negatively affect shareholder value.

Key Dates

Keywords

Form 4, Beneficial Ownership, Restricted Stock Units, Vesting, Tax Withholding, Interpace Biosciences, IDXG, Christopher McCarthy, CFO